Luba Yammine1, Lorraine Frazier2, Nikhil S Padhye3, Matthew M Burg4, Janet C Meininger3. 1. University of Texas Health Science Center at Houston, United States. Electronic address: Luba.Yammine@uth.tmc.edu. 2. University of Arkansas for Medical Sciences, Little Rock, United States. 3. University of Texas Health Science Center at Houston, United States. 4. Columbia University, Center for Behavioral Cardiovascular Health, United States; Yale University, Section of Cardiovascular Medicine, United States.
Abstract
OBJECTIVE: To explore the relationship of depressive symptom severity to circulating endothelin (ET)-1 in younger patients with acute coronary syndrome (ACS). Younger patients report greater depressive symptom severity, which predicts poorer post-ACS prognosis. The pathways linking depression to post-ACS prognosis require further elucidation. ET-1 is a potent endogenous vasoconstrictor which has been previously linked to adverse post-ACS outcomes. METHODS: The sample (n=153) included males ≤ 50 years of age and females ≤ 55 years of age who participated in a larger study. Blood samples for ET-1 assessment were collected within 2-3h of ACS admission. Depressive symptoms were assessed with the Beck Depression Inventory (BDI) II within 2-5 days of admission. ET-1 was treated as a transformed continuous variable (ET-1T). BDI-II scores were classified into four categories using conventional thresholds demarcating mild, moderate, and severe levels of depressive symptoms. The relationship of classified BDI-II score to ET-1T was examined in simple and multivariable linear regression models. RESULTS: Classified BDI-II score was related to ET-1T in both unadjusted (χ(2)=9.469, p=0.024) and multivariable (χ(2)=8.430, p=0.038) models, with ET-1T being significantly higher in patients with severe depressive symptoms than in those with mild and moderate depressive symptoms. CONCLUSIONS: In this sample of younger post-ACS patients, severe depressive symptoms were associated with elevated ET-1. We acknowledge that the observed association could be eliminated by the inclusion of some unmeasured variable(s). Longitudinal research should examine whether ET-1 mediates the relationship of depressive symptoms to long-term post-ACS outcomes.
OBJECTIVE: To explore the relationship of depressive symptom severity to circulating endothelin (ET)-1 in younger patients with acute coronary syndrome (ACS). Younger patients report greater depressive symptom severity, which predicts poorer post-ACS prognosis. The pathways linking depression to post-ACS prognosis require further elucidation. ET-1 is a potent endogenous vasoconstrictor which has been previously linked to adverse post-ACS outcomes. METHODS: The sample (n=153) included males ≤ 50 years of age and females ≤ 55 years of age who participated in a larger study. Blood samples for ET-1 assessment were collected within 2-3h of ACS admission. Depressive symptoms were assessed with the Beck Depression Inventory (BDI) II within 2-5 days of admission. ET-1 was treated as a transformed continuous variable (ET-1T). BDI-II scores were classified into four categories using conventional thresholds demarcating mild, moderate, and severe levels of depressive symptoms. The relationship of classified BDI-II score to ET-1T was examined in simple and multivariable linear regression models. RESULTS: Classified BDI-II score was related to ET-1T in both unadjusted (χ(2)=9.469, p=0.024) and multivariable (χ(2)=8.430, p=0.038) models, with ET-1T being significantly higher in patients with severe depressive symptoms than in those with mild and moderate depressive symptoms. CONCLUSIONS: In this sample of younger post-ACS patients, severe depressive symptoms were associated with elevated ET-1. We acknowledge that the observed association could be eliminated by the inclusion of some unmeasured variable(s). Longitudinal research should examine whether ET-1 mediates the relationship of depressive symptoms to long-term post-ACS outcomes.
Authors: Carla Costa Dias; Pedro S Mateus; Carlos Mateus; Nuno Bettencourt; Lino Santos; Luís Adão; Francisco Sampaio; Conceição Fonseca; Lino Simões; Rui Coelho; Vasco G Ribeiro Journal: Rev Port Cardiol Date: 2005-04 Impact factor: 1.374
Authors: Anna L Marsland; Peter J Gianaros; Aric A Prather; J Richard Jennings; Serina A Neumann; Stephen B Manuck Journal: Psychosom Med Date: 2007-10-17 Impact factor: 4.312
Authors: H Ehrenreich; R W Anderson; C H Fox; P Rieckmann; G S Hoffman; W D Travis; J E Coligan; J H Kehrl; A S Fauci Journal: J Exp Med Date: 1990-12-01 Impact factor: 14.307
Authors: Luba Yammine; Lorraine Frazier; Nikhil S Padhye; Jennifer E Sanner; Matthew M Burg Journal: J Psychosom Res Date: 2017-05-23 Impact factor: 3.006
Authors: Christopher M Celano; Eleanor E Beale; Scott R Beach; Arianna M Belcher; Laura Suarez; Shweta R Motiwala; Parul U Gandhi; Hanna Gaggin; James L Januzzi; Brian C Healy; Jeff C Huffman Journal: Psychosom Med Date: 2017-04 Impact factor: 4.312
Authors: Radwa N Muhammad; Lamiaa A Ahmed; Rania M Abdul Salam; Kawkab A Ahmed; Amina S Attia Journal: Neurotherapeutics Date: 2021-10-18 Impact factor: 6.088
Authors: Elizabeth N Madva; Christopher M Celano; Diana M Smith; James L Januzzi; Jeff C Huffman Journal: J Psychosom Res Date: 2020-11-11 Impact factor: 3.006